Akari Therapeutics wins Australian patent acceptance for Thailanstatin analog ADC payload
PUBT · 04/27 12:40
Share
Listen to the news
- Akari Therapeutics reported acceptance of an Australian patent application covering its PH1 RNA splicing modulator ADC payload technology.
- Patent application 2024201765 includes composition-of-matter claims for second-generation Thailanstatin analogs intended for use in cancer-targeting ADCs.
- Protection supports Akari ADC pipeline, including AKTX-101 and AKTX-102, which use the PH1 payload.
- Akari expects AKTX-101 to enter Phase 1 first-in-human testing in late 2026 or early 2027 following IND-enabling studies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved